Bayesian interpretation of febrile neutropenia risk and primary granulocyte colony-stimulating factor prophylaxis during darolutamide triplet therapy
Abstract
To the Editor: We read with great interest the article titled “Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel” by Uchimoto et al. [1]. In 137 patients treated between February 2023 and February 2025, they reported substantial prostate-specific antigen responses and no statistically significant differences in short-term efficacy or safety between patients aged
Fields of Study & Subjects
Neutropenia and Cancer Infections
Blood disorders and treatments
Immune Response and Inflammation
Publication details
- Journal / source
- Japanese Journal of Clinical Oncology
- Publisher
- Oxford University Press (OUP)
- Volume
- 56
- Issue
- 8
- Pages
- 1022–1023
- Publication date
- 25 March 2026
- Language
- EN